Subject
Clinical Biochemistry,Spectroscopy,Drug Discovery,Pharmaceutical Science,Analytical Chemistry
Reference18 articles.
1. Essential thrombocythemia treatment algorithm 2018;Tefferi;Blood Cancer J.,2018
2. Anagrelide platelet‐lowering effect is due to inhibition of both megakaryocyte maturation and proplatelet formation: insight into potential mechanisms;Espasandin;J. Thromb. Haemost.,2015
3. Tefferi, A.; Silverstein, M.N.; Petitt, R.M.; Mesa, R.A.; Solberg, L.A.Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of action, efficacy, toxicity, current indications, Seminars in thrombosis and hemostasis, Copyright© 1997 by Thieme Medical Publishers, Inc.: 1997; pp 379–383.
4. Comparison of the biological activities of anagrelide and its major metabolites in haematopoietic cell cultures;Wang;Br. J. Pharmacol.,2005
5. A development and validation of RP-HPLC method for the determination of degradation impurities in anagrelide dosage form;Mallavarapu;Anal. Chem. Lett.,2021